Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yamada, Kohji ^a   Hayashi, Mutsumi ^a   Madokoro, Hiroko ^a   Nishida, Hiroko ^a   Du, Wenlin ^a   Ohnuma, Kei ^b   Sakamoto, Michiie ^a   Morimoto, Chikao ^b   Yamada, Taketo ^a  

^a KEIO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; DIPEPTIDYL PEPTIDASE IV; MONOCLONAL ANTIBODY; RNA POLYMERASE II; UNCLASSIFIED DRUG; YS 110;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DELETION MUTANT; DNA FLANKING REGION; DRUG RESPONSE; EMBRYO; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; POLR2A GENE; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; T CELL LEUKEMIA; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ACTIVE TRANSPORT; ANIMAL; CELL TRANSFORMATION; EXTRACELLULAR SPACE; GENETIC TRANSCRIPTION; GENETICS; GENOMICS; IMMUNOLOGY; LUNG TUMOR; MESOTHELIOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIPEPTIDYL PEPTIDASE 4; EXTRACELLULAR SPACE; GENOMICS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; RNA POLYMERASE II; TRANSCRIPTION, GENETIC;

EID: 84876901284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062304     Document Type: Article

References (50)

1. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N, (2003) Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 10: 19-25.
2. Drucker DJ, Nauck MA, (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
3. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, et al. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 13: 1634-1645.
4. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, et al. (2007) Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 13: 4191-4200.
5. Pang R, Law WL, Chu AC, Poon JT, Lam CS, et al. (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6: 603-615.
6. Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, et al. (2011) Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun 404: 735-742.
7. Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, et al. (2011) Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncol Rep 26: 1369-1375.
8. Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, et al. (2012) CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma. Clin Cancer Res 18: 1447-1456.
9. Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, et al. (2006) Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 12: 3470-3477.
10. Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, et al. (2001) In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7: 2031-2040.
11. Adams GP, Weiner LM, (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
12. Steplewski Z, Lubeck MD, Koprowski H, (1983) Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221: 865-867.
13. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, et al. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70.
14. Weng WK, Levy R, (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947.
15. Benmerah A, (2004) Endocytosis: signaling from endocytic membranes to the nucleus. Curr Biol 14: R314-316.
16. Miaczynska M, Bar-Sagi D, (2010) Signaling endosomes: seeing is believing. Curr Opin Cell Biol 22: 535-540.
17. Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, et al. (1997) Nuclear accumulation of fibroblast growth factor receptors in human glial cells-association with cell proliferation. Oncogene 14: 2201-2211.
18. Wang YN, Yamaguchi H, Hsu JM, Hung MC, (2010) Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 29: 3997-4006.
19. Lin-Lee YC, Pham LV, Tamayo AT, Fu L, Zhou HJ, et al. (2006) Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 281: 18878-18887.
20. Yamada K, Hayashi M, Du W, Ohnuma K, Sakamoto M, et al. (2009) Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. Cancer Cell Int 9: 17.
21. Kotani T, Kawano J, Suganuma T, Hirai K, Umeki K, et al. (1992) Immunohistochemical localization of dipeptidyl aminopeptidase IV in thyroid papillary carcinoma. Int J Exp Pathol 73: 215-222.
22. Ohnuma K, Ishii T, Iwata S, Hosono O, Kawasaki H, et al. (2002) G1/S cell cycle arrest provoked in human T cells by antibody to CD26. Immunology 107: 325-333.
23. Wintzerith M, Acker J, Vicaire S, Vigneron M, Kedinger C, (1992) Complete sequence of the human RNA polymerase II largest subunit. Nucleic Acids Res 20: 910.
24. Kittler JT, Thomas P, Tretter V, Bogdanov YD, Haucke V, et al. (2004) Huntingtin-associated protein 1 regulates inhibitory synaptic transmission by modulating gamma-aminobutyric acid type A receptor membrane trafficking. Proc Natl Acad Sci U S A 101: 12736-12741.
25. Fairfax BP, Pitcher JA, Scott MG, Calver AR, Pangalos MN, et al. (2004) Phosphorylation and chronic agonist treatment atypically modulate GABAB receptor cell surface stability. J Biol Chem 279: 12565-12573.
26. Nojima T, Hirose T, Kimura H, Hagiwara M, (2007) The interaction between cap-binding complex and RNA export factor is required for intronless mRNA export. J Biol Chem 282: 15645-15651.
27. Kounnis V, Ioachim E, Svoboda M, Tzakos A, Sainis I, et al. (2011) Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets. Onco Targets Ther 4: 27-32.
28. Yamamoto H, Komekado H, Kikuchi A, (2006) Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 11: 213-223.
29. McMahon HT, Boucrot E, (2011) Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12: 517-533.
30. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R, (2007) A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8: 848-866.
31. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, et al. (2007) Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 282: 10117-10131.
32. Sonnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M, (2000) Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J Cell Biol 149: 901-914.
33. Zerial M, McBride H, (2001) Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2: 107-117.
34. Giri DK, Ali-Seyed M, Li LY, Lee DF, Ling P, et al. (2005) Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 25: 11005-11018.
35. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, et al. (2006) Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 98: 1570-1583.
36. Calera MR, Zamora-Ramos C, Araiza-Villanueva MG, Moreno-Aguilar CA, Pena-Gomez SG, et al. (2011) Parcs/Gpn3 is required for the nuclear accumulation of RNA polymerase II. Biochim Biophys Acta 1813: 1708-1716.
37. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, et al. (2001) Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 155: 755-762.
38. Wang SC, Hung MC, (2009) Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 15: 6484-6489.
39. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, et al. (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6: 251-261.
40. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, et al. (1991) Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 13: 15-20.
41. Mook OR, Baas F, de Wissel MB, Fluiter K, (2009) Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A. Cancer Gene Ther 16: 532-538.
42. Sudo H, Tsuji AB, Sugyo A, Kohda M, Sogawa C, et al. (2010) Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model. Genomics 95: 210-216.
43. Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, et al. (2005) Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 280: 19166-19176.
44. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, et al. (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 87: 600-607.
45. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, et al. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345: 241-247.
46. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, et al. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678-3684.
47. Weiner LM, Murray JC, Shuptrine CW, (2012) Antibody-based immunotherapy of cancer. Cell 148: 1081-1084.
48. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, et al. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5: 98-101.
49. Rakowicz-Szulczynska EM, Koprowski H, (1989) Nuclear uptake of monoclonal antibody to a surface glycoprotein and its effect on transcription. Arch Biochem Biophys 271: 366-379.
50. Rakowicz-Szulczynska EM, Steplewski Z, Koprowski H, (1992) Nuclear translocation of monoclonal antibody directed against cell-surface carbohydrate Y determinant. Am J Pathol 141: 937-947.